Live Breaking News & Updates on Tki therapy

Stay updated with breaking news from Tki therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management

Explore dosing nuances and adverse event management strategies for afatinib in treating EGFR mutant non-small cell lung cancer, reflecting real-world practices and clinical insights.

Precision-medicine , Biomarker-testing , Afatinib-use , Dosing-strategies , Adverse-event , Nsclc , Non-small-cell-lung-cancer , Afatinib , Afatinib-dosing , Egfr-mutant-nsclc , Adverse-event-management

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment.

Bijal-shah , Hagop-kantarjian , Expert-insights , Newly-diagnosed , Frontline-therapy , Acute-lymphoblastic-leukemia , Call-cancer , Oph-all , Ph-acute-lymphoblastic-leukemia , Philadelphia-chromosome-positive-acute-lymphoblastic-leukemia , Newly-diagnosed-all

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.

Elias-jabbour , First-report , Comparing-ponatinib , Newly-diagnosed , Acute-lymphocytic-leukemia , Call-cancer , All-leukemia , Ponatinib , Imatinib , Phallcon , Ph-positive

Novel Combination Strategies in mCRC: The STELLAR-303 and SUNLIGHT Trials

Before closing out their review of combination therapy in metastatic colorectal cancer, panelists discuss the STELLAR-303 and SUNLIGHT clinical trials.

Metastatic-colorectal-cancer-with , Positive-disease , Combination-strategies , Colorectal-cancer , Crc , Metastatic-crc , Dmcrc , Immunotherapy , Immune-checkpoint-inhibitors , Tki-therapy , Tyrosine-kinase-inhibitors

Combination IO/TKI Strategies in Metastatic Colorectal Cancer

A comprehensive review on combination strategies with immune checkpoint and tyrosine kinase inhibitors in patients with metastatic colorectal cancer.

Metastatic-colorectal-cancer-with , Positive-disease , Metastatic-colorectal-cancer , Colorectal-cancer , Crc , Metastatic-crc , Dmcrc , Immunotherapy , Immune-checkpoint-inhibitors , Tki-therapy , Tyrosine-kinase-inhibitors